SINGAPORE, Jan. 23, 2026 /PRNewswire/ -- Mining Asia (https://www.miningasiaconvention.com), South East Asia's largest and longest standing mining conference and exhibition showcasing the region's dynamic mining sector to an international audience of investors, industry leaders and key mining stakeholders, is returning to Singapore Marina Bay Sands Expo and Convention Centre from 23-24 June 2026.
For the 2026 edition, Mining Asia expands its focus to include clean energy technologies, batteries, EVs and renewable energy within its conference themes. This evolution reflects the industry's shift towards sustainable mining practices and integration of green technologies across mining operations.
Clean energy, batteries and renewables for Mining Asia
The current energy transition to deliver a clean energy future – powered by renewable energy and electric vehicles - is a defining conversation of our time. For South East Asia, this transition carries particular urgency as the region faces escalating impacts of climate change, including record breaking heat waves, severe droughts and rising sea levels.
Mining Asia has long been at the forefront of championing the South East Asian and wider Asian mining sector, recognizing mining's vital role as a key economic driver for the region. As the world pivots away from coal and accelerates the shift towards clean energy, critical minerals such as nickel, lithium and rare earths have become essential to reducing dependence on fossil fuels.
With Asia Pacific countries such as Indonesia, China and Australia emerging as major critical minerals producers, Singapore's strategic location and reputation as a global finance hub position it as the ideal gateway for fostering investments and dialogue on clean energy, batteries and renewables. Mining Asia thus serves as the premier platform to shape the region's sustainable energy future.
Attendee profile
More than 70% of attendees at Mining Asia come from Asia and the Middle East while Australia, Europe and Americas make up the remaining 30%. This strong regional presence makes Mining Asia the ideal platform for international mining and energy companies seeking to connect with Asia based investors and showcase their projects to a highly targeted audience.
Our investor base includes banks, institutional and private investors, all seeking new opportunities in the mining, energy and clean technology sectors. This qualified investor pool continues to grow yearly, underscoring Mining Asia's proven ability to attract new investors to the event.
Daniel Radziszewski, Managing Director of Spire Events – organisers of Mining Asia since 2015 - states that "Over the past 11 years, the high quality of the speakers assembled at this event has provided insightful regional and international perspectives, leading to Mining Asia being recognised as the leading event in the region for global companies and individuals who wish to understand what makes South East Asia mining industry tick."
He added, "Regular attendees at Mining Asia over the past decade have given feedback that they appreciate the diversity of conference topics, speakers and exhibitors as it provides useful opportunities to learn latest industry developments and establish new business contacts".
Spaces are available for sponsors, exhibitors and delegates who wish to be a part of Mining Asia 2026. Enquiries can be sent to Daniel via email at daniel.radz@spire-events.com. More information is available at https://www.miningasiaconvention.com
Background on Spire Events
Spire Events is a Singapore based events company specialising in mining & energy conferences and expos. Mining Asia is part of the global Critical Minerals, Mining & Clean Energy Conference Series that spans across various locations in Asia, Europe, Latin and North America and Australia.
Spire Events also organises the MiningTech Conference Series which focuses on technology in mining and they are held in Brazil and Canada. Besides conferences, Spire Events also organises large scale mining and energy expos in Africa, namely Mauritania and Botswana. The full calendar of events can be found at www.spire-events.com
PR Newswire is the Official Press Release Distribution Partner of Mining Asia Conference and Expo
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
11th Annual Mining Asia Conference & Expo Incorporates Clean Energy, Renewables & Batteries for the 2026 edition
In the news release, CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year, issued 10-Sep-2026 by CordenPharma over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year
CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional aseptic fill & finish lines
BASEL, Switzerland, Sept. 10, 2026 /PRNewswire/ -- CordenPharma continues its ambitious long-term injectable CAPEX program at its FDA & EMA-approved Caponago (Milan), Italy site, reinforcing its position as a global leader in sterile injectable manufacturing. The expansion involves two key components to augment manufacturing capacity for sterile injectable drug products.
Firstly, the company has committed a multi-year €80 million investment into the future of injectable drug products, marking a significant milestone of that total with a €13 million acquisition of a new 11,000 m² commercial building and 26,000 m² of land, adjacent to its existing late-stage aseptic fill & finish manufacturing area. This expansion was finalized on 28 July 2026, increasing the site footprint by greater than 50%.
The new facility offers a blank canvas ideal for innovators seeking fit-for-purpose aseptic fill & finish CDMO outsourcing of their peptide, LNP, small molecule, biologic, and oligonucleotide-based injectable therapeutics, tailored to their specific production setups and requirements. The expanded capacity is a versatile foundation for the integration of additional manufacturing lines supporting a wide range of injectable formats including Pre-Filled Syringes (PFS), liquid or lyophilized vials, cartridges, and auto-injectors. Customers will also benefit from a single-site offering injectable solutions integrated with LNP manufacturing capabilities on the same campus at CordenPharma Caponago.
The space can accommodate a minimum of four aseptic fill & finish lines, four visual inspection lines, and four additional packaging lines, with options for customer-owned lines, large-scale lyophilization, and auto-injector assembly.
Secondly, over the past two years, CordenPharma has embarked on a series of strategic expansions at an existing operational area within its Caponago site that immediately contributes to the increased injectable capacity by adding two new aseptic fill & finish isolator lines. These include:
- A clinical and small-scale commercial combo line from Bausch & Ströbel for Pre-Filled Syringes (PFS), vials, and cartridges.
- A high-speed PFS & cartridge line from Syntegon, capable of producing >500,000 units per day.
- Expansion of the automatic secondary packaging area for PFS, vials, and ampoules.
- A doubling of analytical capacity to support growing project pipelines.
Completion of the new isolator lines is targeted for mid-2027 and 2028 respectively, ensuring CordenPharma remains at the forefront of sterility assurance and long-term compliance during sterile injectable manufacturing.
The investment in these new and expanded facilities underscores a proactive approach to addressing the global healthcare industry's increasing need for specialized injectable manufacturing. With these combined investment milestones bolstering a landmark scale-up in production with a projected total capacity up to 500 million injectable units per year, CordenPharma is poised to support innovators across their injectable drug lifecycle from early-phase projects to large-scale commercial production.
This capacity surge helps meet the rising global demand for sterile injectable outsourcing across therapeutic areas such as oncology, obesity, diabetes and Inflammatory diseases with complex modalities such as peptide-based GLP-1 therapeutics, oligonucleotides, LNPs, biosimilars and other biologics.
The company's customers will also gain valuable access to integrated solutions from drug substance to drug products, leveraging CordenPharma's global facility network and expertise in manufacturing peptides (including oral peptide drug products), oligonucleotides, non-viral carriers such as LNPs, and small molecules, including both highly potent and non-potent APIs.
Dr. Michael Quirmbach, President & CEO of CordenPharma Group, commented: "The support of our shareholders, Astorg, underscores our commitment to advancing sterile injectable manufacturing at CordenPharma Caponago. This strategic investment strengthens our leadership in the manufacture of drug products using complex modalities and enhances our end-to-end supply capabilities to meet rising global demand for injectable outsourcing, ultimately enabling partners to bring vital drug products in key therapeutic areas to patients more efficiently."
About CordenPharma
CordenPharma is a CDMO supporting and partnering with biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.
With scientific expertise and partnership at its core, CordenPharma provides customers with high-value, end-to-end services with a strategic focus on Peptides, Small Molecules (both Highly Potent and Regular Potency), customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and Oligonucleotides.
The CordenPharma Group is comprised of 13 facilities across Europe, North America and Asia with more than 3,500 employees. In the 2025 financial year, the organization generated sales of €960 million. In 2022, CordenPharma was acquired by Astorg - a leading Pan-European private equity firm with deep expertise in the healthcare sector - to accelerate its development and further strengthen its leadership in the CDMO space.
Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year
